Skip to content
Parker Institute for Cancer Immunotherapy
Search Close

LumaBridge and the Parker Institute for Cancer Immunotherapy Form Strategic Alliance to Speed Access to Clinical Trial Services for Partners

LumaBridge, a clinical research organization that discovers, develops and tests emerging biotherapeutics for cancer, and the Parker Institute for Cancer Immunotherapy (PICI), a network of the largest concentration of immuno-oncology (IO) expertise in the world, today announced a strategic partnership to accelerate breakthrough immunotherapies from bench to bedside faster and with greater ease. The collaboration offers affiliated scientists and organizations a one-stop shop to advance research studies, and establishes LumaBridge as PICI’s first valued clinical research organization (CRO) partner.

The organizations are collaborating to provide PICI Affiliated Partners, including PICI Network research institutions and investigators, affiliated companies and nonprofit collaborators, direct access to a full suite of clinical trial services from LumaBridge, which formerly was known as Cancer Insight. Those services range from clinical trial design to regulatory strategy support including patient accrual, clinical operations, quality assurance, data management, medical writing, biostatistics and pharmacovigilance.

“PICI was founded to clear the path from scientific idea to best possible clinical outcomes,” said Ute Dugan, MD, PhD, chief medical officer of PICI. “By providing PICI Affiliated Partners access to LumaBridge’s clinical trial design and oversight services, we aim to streamline the development process and ultimately accelerate approval of novel immunotherapies for patients.”

Through this mission-focused alliance, PICI Affiliated Partners gain preferred access and pricing to an array of clinical trial services and expertise. This includes early consulting on clinical trial design and development, protocol development, regulatory support and full-service clinical trial support.

“Patients awaiting new therapies deserve an effective, efficient process,” said George E. Peoples, MD, FACS, founder and chief medical officer of LumaBridge. “Like PICI, LumaBridge is focused on bringing more immunotherapies to patients faster through new forms of research collaborations, and innovative science and technologies. Through this partnership, we will unite our pioneering experience in immuno-oncology development with the expertise of academic, clinical and industry partners affiliated with PICI to reduce turnaround time and safely test the most promising novel therapies for cancer patients.”

Available LumaBridge services include:

  • Regulatory support for pre-investigational new drug meetings and investigational new drug (IND) preparation, publishing, filing and maintenance of IND applications.
  • Clinical trial design, execution and support such as medical monitoring, clinical operations, data management and quality assurance.
  • Medical writing and biostatistics support such as statistical analysis, U.S. Food and Drug Administration application writing and abstract or journal publication preparation.
  • Guidance in navigating government and military contracts and funding.
  • Clinical development and commercialization strategies for Cancer Prevention and Research Institute of Texas applicants.

“The power of our bench-to-bedside-to-market model lies in collaboration,” said Tarak Mody, PhD, chief business officer of PICI. “By offering PICI Affiliated Partners access to LumaBridge’s services and expertise, we are enabling discoveries to get to the clinic and to patients sooner through streamlined, efficient clinical development.”

About the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done. Founded in 2016 through a $250 million gift from Silicon Valley entrepreneur and philanthropist Sean Parker, the San Francisco-based nonprofit is an unprecedented collaboration between the country’s leading immunotherapy researchers and cancer centers. The PICI Network of research institutions includes Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania, and The University of Texas MD Anderson Cancer Center. The institute also supports top researchers at other institutions, including the Dana-Farber Cancer Institute, City of Hope, Fred Hutchinson Cancer Research Center, Icahn School of Medicine at Mount Sinai, Institute for Systems Biology, and Washington University School of Medicine in St. Louis. By forging alliances with academic, industry, and nonprofit partners, PICI makes big bets on bold research to fulfill its mission: to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases. Find out more at, and follow us on LinkedIn and Twitter @parkerici.

About LumaBridge

LumaBridge is a specialty clinical research organization (CRO) focused on creating innovative clinical trial solutions for biopharma companies. Founded in 2014 as Cancer Insight, the company offers customized clinical trial guidance, strategic partnership and personalized attention to each sponsor, accelerating the development of potential therapies. LumaBridge builds on the success and experience of a seasoned team, led by Dr. George Peoples, to support drug development, accelerating therapies to patients and guiding biopharma companies through clinical and regulatory pathways. As part of their comprehensive CRO services, LumaBridge offers consultation on trial design and clinical development strategy. For more information, visit

Media Contacts

Parker Institute for Cancer Immunotherapy
Laurie Peters